# A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Source: https://onco.cc/trials/nct07367529/  
OnCo record `nct07367529` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TQB6411 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection is a phase 1/2 interventional study registered as NCT07367529 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 465 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12. Interventions recorded: TQB6411 for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07367529
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 465

## Sources

- ClinicalTrials.gov NCT07367529: https://clinicaltrials.gov/study/NCT07367529

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [TQB6411](https://onco.cc/drugs/tqb6411/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07367529.json